WuXi AppTec Completes Acquisition Of HD Biosciences Co., Ltd
Published: May 15, 2017
SHANGHAI, May 15, 2017 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has completed its acquisition of HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO).
Headquartered in Shanghai, HD Biosciences is a leading biology and preclinical service provider. Its plate-based pharmacology & screening capability and AGMTM based target validation are industry leading platforms with great reputation. The company also provides hit identification, lead discovery, in vivo pharmacology and other related services. The acquisition will further strengthen WuXi's R&D capability from target validation to lead discovery and optimization, improving and expanding WuXi's open-access enabling service platform.
"My colleagues and I are very excited to be part of WuXi AppTec family," said Dr. Xuehai Tan, Chairman and CEO of HD Biosciences. "The merger will provide additional resources and space to, take our biology focused capabilities to a next level and to speed up the growth of our business into a leading global player within our sector. We will provide better services to our current clients and potentially expand services to WuXi's global customers." Dr. Xuehai Tan will become a Senior Vice President of WuXi AppTec, and the President of HD Biosciences. HD Bioscience will become a wholly owned subsidiary of WuXi AppTec and a member of WuXi's Research Service Division and continue to focus on its core capabilities and business growth.
"We are very pleased to have HD Biosciences join the WuXi team," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi AppTec. "This business combination is an important step in WuXi's development of the most comprehensive capability and technology platform in industry to enable anyone, and any company to discover and develop better medicines and healthcare products for patients, and to realize our vision that 'every drug can be made and every disease can be treated'."
About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit http://www.wuxiapptec.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wuxi-apptec-completes-acquisition-of-hd-biosciences-300457448.html
SOURCE WuXi AppTec